Conditions:  Refractory Endometrial Adenocarcinoma;  Refractory Endometrial Carcinoma;  Refractory Endometrial Clear Cell Adenocarcinoma;  Refractory Endometrial Endometrioid Adenocarcinoma;  Refractory Endometrial Mixed Cell Adenocarcinoma;  Refractory Endometrial Serous Adenocarcinoma;  Refractory Endometrial Undifferentiated Carcinoma
Interventions:  Drug: Extended-release Onapristone;  Drug: Anastrozole;  Other: Quality-of-Life Assessment;  Other: Questionnaire Administration
Sponsors:  Thomas Jefferson University;  National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions:  Drug: Extended-release Onapristone;  Drug: Anastrozole;  Other: Quality-of-Life Assessment;  Other: Questionnaire Administration
Sponsors:  Thomas Jefferson University;  National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
